Treasury Chief Rachel Reeves Intends Targeted Action on Living Costs in Upcoming Financial Plan
Chancellor Reeves has stated she is preparing "focused action to address cost of living pressures" in the forthcoming financial statement.
During an interview with media outlets, she noted that reducing price rises is a joint duty of both the administration and the Bank of England.
The United Kingdom's inflation rate is expected to be the highest among the Group of Seven developed nations this year and next.
Possible Utility Cost Interventions
Sources suggest the administration could intervene to reduce energy bills, such as by reducing the present 5% level of value-added tax charged on energy supplies.
A further option is to lower some of the government charges currently included in bills.
Budgetary Limitations and Analyst Expectations
The administration will receive the latest report from the independent fiscal watchdog, the Office for Budget Responsibility, on Monday, which will show how much room there is for such actions.
The view from most analysts is that Reeves will have to announce tax rises or expenditure reductions in order to meet her voluntary borrowing rules.
Earlier on the same day, calculations indicated there was a £22bn shortfall for the Treasury chief to address, which is at the lower end of projections.
"It is a shared task between the Bank of England and the administration to bear down further on some of the causes of inflation," Reeves told reporters in Washington, at the conferences of the International Monetary Fund and World Bank.
Tax Commitments and International Concerns
While a great deal of the focus has been on expected tax increases, the Treasury chief said the most recent figures from the fiscal watchdog had not changed her vow to manifesto promises not to raise tax levels on earnings tax, VAT or social security contributions.
She blamed an "uncertain global environment" with growing geopolitical and commercial issues for the Budget tax moves, likely to be directed on those "most able to pay."
International Trade Tensions
Commenting on worries about the United Kingdom's trade ties with China she said: "Our national security invariably are paramount."
Last week's announcement by Chinese authorities to strengthen trade restrictions on rare earths and other resources that are key for advanced tech manufacturing led US President Donald Trump to propose an extra 100% tariff on imports from the Asian country, raising the risk of an all-out trade war between the two largest economies.
The American finance chief labeled the Chinese action "economic coercion" and "a international production control attempt."
Asked about accepting the American proposal to join its conflict with the Asian nation, Reeves said she was "extremely troubled" by China's measures and called on the Beijing authorities "not to put up barriers and limit trade."
She said the decision was "bad for the international commerce and creates further challenges."
"In my view there are areas where we must address China, but there are also important opportunities to sell into Chinese markets, including banking sector and other sectors of the economy. We've got to maintain that balance appropriate."
The chancellor also confirmed she was cooperating with other major economies "regarding our own critical minerals plan, so that we are reduced dependence."
NHS Drug Pricing and Investment
Reeves also admitted that the price the NHS spends on drugs could go up as a consequence of ongoing discussions with the US government and its drugs companies, in exchange for lower tariffs and funding.
Some of the biggest global drug companies have said lately that they are either delaying or scrapping projects in the United Kingdom, with several blaming the insufficient payments they are obtaining.
Recently, the government science advisor said the cost the NHS pays for drugs would have to increase to stop firms and pharmaceutical investment departing from the United Kingdom.
The Chancellor told the BBC: "It has been observed as a result of the pricing regime, that clinical trials, recent pharmaceuticals have not been provided in the UK in the manner that they are in other European countries."
"The objective is to ensure that patients getting care from the National Health Service are can receive the finest life-saving drugs in the globe. And so we are reviewing this situation, and... aiming to attract increased capital into Britain."